Abbas Bitar, MD
Advanced Heart Failure and Transplant Cardiology · Ann Arbor, MINPI 1174836928
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,400 of the $8,174 with a category attached, or 90.5%. 3 manufacturers reported payments, led by Novo Nordisk at 56.9% of the total. Reporting peaked in 2023 at $4,650 and has fallen 99.1% since, to $44 in 2024.
Across 18 payments — averaging $454.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$5K
- Abbott$3K
- Procyrion, Inc.$60
Across 53 payments — averaging $11,617 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$307K
- Briohealth Solutions, Inc.$139K
- Procyrion, Inc.$136K
- Amgen$34K
What the payments were for
- Consulting fees$7,40091%
- Travel & lodging$5166%
- Food & beverage$2483%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 2 | $4,650 |
| Abbott | 12 | $3,464 |
| Procyrion, Inc. | 4 | $60 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,174 in reported general payments places this provider in the 70th percentile of 27 advanced heart failure and transplant cardiology providers in Michigan.
See all advanced heart failure and transplant cardiology providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GalafoldMigalastat Hcl | 12 | $359,421 |
| EliquisApixaban | 255 | $312,247 |
| JardianceEmpagliflozin | 184 | $268,231 |
| EntrestoSacubitril/Valsartan | 110 | $124,808 |
| FarxigaDapagliflozin Propanediol | 120 | $116,273 |
| XareltoRivaroxaban | 66 | $78,850 |
| VeltassaPatiromer Calcium Sorbitex | 16 | $34,249 |
| Repatha SureclickEvolocumab | 22 | $14,962 |
| Praluent PenAlirocumab | 26 | $12,002 |
| Isosorbide Dinitrate | 43 | $9,641 |
| Metoprolol Succinate | 407 | $8,567 |
| Torsemide | 216 | $5,534 |
| Spironolactone | 464 | $5,358 |
| Atorvastatin Calcium | 224 | $3,693 |
| Bumetanide | 58 | $3,598 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Ann Arbor
- Thomas CascinoAnn Arbor$39K
- Keith AaronsonAnn Arbor$22K
- Scott HummelAnn Arbor$1K
- Maryse PalardyAnn Arbor$910
- Marty TamAnn Arbor$243
- Yoav HammerAnn Arbor$150
- Matthew KonermanAnn Arbor$135
- Rosanne RoufAnn Arbor$39
- Daniel GoldsteinAnn Arbor$20
- John NicklasAnn Arbor$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.